Rezafungin: a novel antifungal for the treatment of invasive candidiasis
Abstract
isolates. Available clinical data show robust safety and promising efficacy. Phase III trials will provide data on efficacy of rezafungin for the treatment of candidemia and invasive candidiasis and for the prevention of invasive fungal disease in blood and bone marrow transplant recipients. Rezafungin is a promising new candidate in the antifungal arsenal that opens up clinical possibilities based on its impressive half-life, such as early hospital discharge for stable patients and use as prophylaxis in immunocompromised patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rezafungin is a novel echinocandin with a broad spectrum of activity and pharmacokinetic advantages over currently available echinocandins.
“Rezafungin is a novel echinocandin with a broad spectrum of activity and pharmacokinetic advantages over currently available echinocandins.”
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Thompson, G. R., Soriano, A., Skoutelis, A., Vazquez, J. A., Honore, P. M., Horcajada, J. P., Spapen, H., Bassetti, M., Ostrosky-Zeichner, L., Das, A. F., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1380 · Cited by 163 · see citing works
Self-citationSafety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161 · see citing works
Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
Ong, V. S., Hough, G., Schlosser, M., Bartizal, K. F., Balkovec, J. M., James, K. D., & Krishnan, B. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00701-16 · Cited by 126 · see citing works
Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris
Berkow, E. L., & Lockhart, S. R. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.10.021 · Cited by 110 · see citing works
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., Jones, R. N., & Castanheira, M. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw214 · Cited by 103 · see citing works
Zhao, Y., Prideaux, B., Nagasaki, Y., Lee, M. H., Chen, P.-Y., Blanc, L., Ho, H., Clancy, C. J., Nguyen, M. H., Dartois, V., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-17 · Cited by 102 · see citing works
Sofjan, A. K., Mitchell, A. C., Shah, D. N., Nguyen, T. H., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.02.013 · Cited by 99 · see citing works
CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility
Krishnan, B. R., James, K. D., Polowy, K., Bryant, B. J., Vaidya, A., Smith, S., & Laudeman, C. P. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.89 · Cited by 98 · see citing works
Hager, C. L., Larkin, E. L., Long, L. A., & Ghannoum, M. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky153 · Cited by 95 · see citing works
Wiederhold, N. P., Locke, J. B., Daruwala, P., & Bartizal, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky280 · Cited by 91 · see citing works
In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Tóth, Z., Forgács, L., Locke, J. B., Kardos, G., Nagy, F., Kovács, R., Szekely, A., Borman, A. M., & Majoros, L. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz390 · Cited by 82 · see citing works
CD101: a novel long-acting echinocandin
Zhao, Y., Perez, W. B., Jiménez‐Ortigosa, C., Hough, G., Locke, J. B., Ong, V., Bartizal, K., & Perlin, D. S. (2016) · Cellular Microbiology · doi:10.1111/cmi.12640 · Cited by 81 · see citing works
Lepak, A. J., Zhao, M., & Andes, D. R. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01572-18 · Cited by 79 · see citing works
Pfaller, M. A., Carvalhaes, C., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00099-20 · Cited by 68 · see citing works
Locke, J. B., Almaguer, A. L., Zuill, D. E., & Bartizal, K. F. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00620-16 · Cited by 66 · see citing works
Pfaller, M. A., Messer, S. A., Rhomberg, P. R., & Castanheira, M. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.03.028 · Cited by 65 · see citing works
Lepak, A. J., Zhao, M., VanScoy, B. D., Ambrose, P. G., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02154-17 · Cited by 63 · see citing works
Helleberg, M., Jørgensen, K. M., Hare, R. K., Datcu, R., Chowdhary, A., & Arendrup, M. C. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02438-19 · Cited by 61 · see citing works
Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species
Ong, V. S., James, K. D., Smith, S. M., & Krishnan, B. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01626-16 · Cited by 52 · see citing works
Bader, J. C., Lakota, E. A., Flanagan, S., Ong, V. S., Sandison, T., Rubino, C. M., Bhavnani, S. M., & Ambrose, P. G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-17 · Cited by 44 · see citing works
Pharmacological basis of CD101 efficacy: exposure shape matters
Lakota, E. A., Bader, J. C., Ong, V., Bartizal, K., Miesel, L., Andes, D. R., Bhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Lepak, A. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00758-17 · Cited by 40 · see citing works
Boikov, D. A., Locke, J. B., James, K. D., Bartizal, K. F., & Sobel, J. D. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx008 · Cited by 37 · see citing works
Chandra, J., & Ghannoum, M. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-17 · Cited by 36 · see citing works
Lepak, A. J., Zhao, M., & Andes, D. R. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01556-19 · Cited by 33 · see citing works
Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects
Flanagan, S., Goodman, D. B., Jandourek, A., O’Reilly, T. E., & Sandison, T. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.757 · Cited by 27 · see citing works
Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy
Jang, S. M., Hough, G., & Mueller, B. A. (2018) · Blood Purification · doi:10.1159/000489212 · Cited by 24 · see citing works
Nyirjesy, P., Alessio, C., Jandourek, A., Lee, J. D., Sandison, T., & Sobel, J. D. (2019) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000473 · Cited by 23 · see citing works
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Wickes, B. L., Catano, G., & Patterson, T. F. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01165-19 · Cited by 23 · see citing works
Rezafungin Prophylactic Efficacy in a Mouse Model of Pneumocystis Pneumonia
Cushion, M. T., & Ashbaugh, A. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.593 · Cited by 7 · see citing works
Flanagan, S. D., Sandison, T., Locke, J. B., Ong, V. S., Ye, G., Bartizal, K. F., & Daruwala, P. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.484 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Architecture of the dynamic fungal cell wall
Gow, N. A. R., & Lenardon, M. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00796-9 · Cited by 447 · see citing works
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449 · see citing works
Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02324-8 · Cited by 192 · see citing works
Self-citationThompson, G. R., & Young, J. H. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027424 · Cited by 192 · see citing works
Self-citationDiagnosis and Treatment of Invasive Candidiasis
Barantsevich, N. E., & Петровна, Б. Е. (2022) · Antibiotics · doi:10.3390/antibiotics11060718 · Cited by 193 · see citing works
Hoenigl, M., Arastehfar, A. A., Arendrup, M. C., Brüggemann, R. J. M., Carvalho, A., Chiller, T. M., Chen, W., Egger, M., Feys, S., Gangneux, J., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00074-23 · Cited by 160 · see citing works
Self-citationThompson, G. R., Soriano, À., Honoré, P. M., Bassetti, M., Cornely, O. A., Kollef, M. H., Kullberg, B. J., Pullman, J. R., Hites, M., Fortün, J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00551-0 · Cited by 83 · see citing works
Self-citationAzim, A., & Ahmed, A. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1256158 · Cited by 75 · see citing works
Understanding the mechanisms of resistance to azole antifungals in Candida species
Li, Y., Hind, C. K., Furner-Pardoe, J., Sutton, J. M., & Rahman, K. M. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf106 · Cited by 66 · see citing works
Aspergillosis: an Update on Clinical Spectrum, Diagnostic Schemes, and Management
Kanaujia, R., Singh, S., & Rudramurthy, S. M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00461-5 · Cited by 63 · see citing works
Jones, C. R., Neill, C., Borman, A. M., Budd, E. L., Cummins, M. N., Fry, C., Guy, R. L., Jeffery, K. J., Johnson, E. M., Manuel, R. J., et al. (2024) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001820 · Cited by 53 · see citing works
Lipopeptides development in cosmetics and pharmaceutical applications: A comprehensive review
Pilz, M., Cavelius, P., Qoura, F., Awad, D., & Brück, T. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108210 · Cited by 47 · see citing works
Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 48 · see citing works
Oliva, A., Rosa, F. G. D., Mikulska, M., Pea, F., Sanguinetti, M., Tascini, C., & Venditti, M. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2240956 · Cited by 40 · see citing works
Fungal cell wall biogenesis: structural complexity, regulation and inhibition
Gow, N. A. R. (2025) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2025.103991 · Cited by 39 · see citing works
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35 · see citing works
The Menace of Candida auris Epidemic Amidst the COVID-19 Pandemic: A Systematic Review
Najeeb, H., Siddiqui, S. A., Anas, Z., Ali, S. H., Usmani, S. U. R., Jawed, F., & Jatoi, H. N. (2022) · Diseases · doi:10.3390/diseases10030058 · Cited by 32 · see citing works
Uniqueness of Candida auris cell wall in morphogenesis, virulence, resistance, and immune evasion
Dakalbab, S., Hamdy, R., Holigová, P., Abuzaid, E. J., Abu-Qiyas, A., Lashine, Y., Mohammad, M. G., & Soliman, S. S. M. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127797 · Cited by 27 · see citing works
Locke, J. B., Pillar, C. M., Castanheira, M., Carvalhaes, C. G., Andes, D. R., Aram, J. A., Andrzejewski, C., Bartizal, K. F., Das, A., Sandison, T., et al. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-23 · Cited by 27 · see citing works
Self-citationSmall molecules for combating multidrug-resistant superbug Candida auris infections
Tu, J., Liu, N., Huang, Y., Yang, W., & Sheng, C. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.001 · Cited by 26 · see citing works
Post-COVID-19 Fungal Infection in the Aged Population
Chavda, V. P., Mishra, T., Kamaraj, S., Punetha, S., Sengupta, O., Joshi, Y., Vuppu, S., Vaghela, D. A., & Vora, L. K. (2023) · Vaccines · doi:10.3390/vaccines11030555 · Cited by 25 · see citing works
Cushion, M. T., & Ashbaugh, A. (2021) · Journal of Fungi · doi:10.3390/jof7090747 · Cited by 25 · see citing works
Antifungal Activity of Mexican Propolis on Clinical Isolates of Candida Species
Rivera-Yañez, C. R., Ruiz-Hurtado, P. A., Reyes‐Reali, J., Mendoza‐Ramos, M. I., Vargas-Dı́az, M. E., Hernández-Sánchez, K. M., Pozo‐Molina, G., Méndez-Catalá, C. F., García-Romo, G. S., Pedroza‐González, A., et al. (2022) · Molecules · doi:10.3390/molecules27175651 · Cited by 24 · see citing works
Biocontrol of Candida albicans by Antagonistic Microorganisms and Bioactive Compounds
Li, H., Yang, J., Zhang, X., Xu, X., Song, F., & Li, H. (2022) · Antibiotics · doi:10.3390/antibiotics11091238 · Cited by 22 · see citing works
Novel avenues for identification of new antifungal drugs and current challenges
Jampílek, J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2097659 · Cited by 19 · see citing works
Insight into advances for the biosynthetic progress of fermented echinocandins of antifungals
Jiang, K., Luo, P., Wang, X., & Lü, L. (2023) · Microbial Biotechnology · doi:10.1111/1751-7915.14359 · Cited by 18 · see citing works
Anti-inflammatory and anticancer p-terphenyl derivatives from fungi of the genus Thelephora
Bailly, C. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116935 · Cited by 17 · see citing works
Management of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review
Pais, M. M., Zaragoza, R., Martín‐Loeches, I., Gómez-Bertomeu, F., & Rodríguez, A. H. (2025) · Journal of Fungi · doi:10.3390/jof11050362 · Cited by 11 · see citing works
Bing, J., Li, S., Ji, L., Du, H., Shamoon, N. M., Nobile, C. J., & Huang, G. (2026) · Clinical Microbiology Reviews · doi:10.1128/cmr.00394-25 · Cited by 12 · see citing works
Candida auris in skilled nursing facilities
Yune, P. S., Coe, J., Rao, M., & Lin, M. Y. (2023) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361231189958 · Cited by 13 · see citing works
Melinte, V., Tudor, A. D., Bujoi, A. G., Radu, M. T., Văcăroiu, C. M., Cismaru, I. M., Holban, T. S., Mîrzan, L., Popescu, R., Ciupan, R. C., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13040325 · Cited by 10 · see citing works
Keck, J. M., Dare, R. K., Jenkins, M. B., Rico, J. C., Grisham, L., McDonald, J. L., Viteri, A., & Bradsher, R. W. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01120-7 · Cited by 11 · see citing works
Zuill, D. E., Almaguer, A. L., Donatelli, J. L., Arendrup, M. C., & Locke, J. B. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad055 · Cited by 10 · see citing works
Sharma, D., & Vázquez, J. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2331775 · Cited by 11 · see citing works
Updated Perspectives on the Diagnosis and Management of Neonatal Invasive Candidiasis
Daniel, K., Greenberg, R. G., Boutzoukas, A. E., & Katakam, L. I. (2023) · Research and Reports in Neonatology · doi:10.2147/rrn.s409779 · Cited by 10 · see citing works
Chastain, D. B., White, B. P., Tu, P. J., Chan, S., Jackson, B., Kubbs, K. A., Bandali, A., McDougal, S., Henao‐Martínez, A. F., & Cluck, D. B. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231175201 · Cited by 10 · see citing works
Soriano, À., Honoré, P. M., Cornely, O. A., Chayakulkeeree, M., Bassetti, M., Haihui, H., Dupont, H., Kim, Y. K., Kollef, M. H., Kullberg, B. J., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae363 · Cited by 9 · see citing works
Self-citationTang, B. H. E., Bay, J. W., Yeong, F. M., & Samuel, M. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101362 · Cited by 10 · see citing works
New pharmacotherapeutic strategies for drug-resistant Candida infections: a review
Raposa, J., & Vázquez, J. A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2433605 · Cited by 8 · see citing works
Yang, S., Wan, F., Zhang, M., Lin, H., Hu, L., Zhou, Z., Wang, D., Zhou, A., Ni, L., Guo, J., et al. (2024) · Journal of Fungi · doi:10.3390/jof10060397 · Cited by 6 · see citing works
Non-superficial Cutaneous Manifestations by Candida Species
Figueroa-Ramos, G., Bermúdez‐Rodríguez, S. P., Gatica‐Torres, M., Barrera‐Godínez, A., Bonifáz, A., & Domínguez‐Cherit, J. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-024-00485-5 · Cited by 6 · see citing works
Molecular Targeting and Novel Therapeutic Approaches against Fungal Infections
Kumar, A., Bansal, P., Katiyar, D., Prakash, G. K. S., & Rao, N. G. R. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230302123310 · Cited by 5 · see citing works
Chastain, D. B., Anderson, D. T., Eudy, J., Henao‐Martínez, A. F., & Cluck, D. B. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag055 · Cited by 4 · see citing works
Safety and efficacy of echinocandin antifungal agents in Candida albicans endophthalmitis
Zhang, Y., Tang, Y. R., Zhou, Y., & Wu, H. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01670-25 · Cited by 2 · see citing works
Hanafy, D. M., & Leaver, D. J. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00568 · Cited by 2 · see citing works
Candida auris: Microbiological Characteristics and Laboratory Diagnosis of the Hidden Pathogen
Servi, E. Y., & Uzun, M. (2022) · Mediterranean Journal of Infection Microbes and Antimicrobials · doi:10.4274/mjima.galenos.2022.2022.28 · Cited by 2 · see citing works
Ostrosky‐Zeichner, L., & Sobel, J. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-35803-6_9 · Cited by 2 · see citing works
Molecular Detection of Candida aaseri in Oral Cavity of Immunocompromised Patients
Rashak, S. J., Al-Maqtoofi, M. Y., & Burghal, A. A. (2024) · Asian Journal of Biology · doi:10.9734/ajob/2024/v20i6418 · Cited by 1 · see citing works
Azzawi, M. A. D. A., Abdat, W., Alhamed, A., Alhothali, A. S. A., Alsheikh, R., Almajed, H. M., Alhamdi, S. I. S., Alshahrani, N. N. A., & Eltayeb, A. O. (2025) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2025.116994 · Cited by 1 · see citing works
Real-world experience with rezafungin for the treatment of biofilm-forming Candida infections
Albanell‐Fernández, M., Soriano, À., Herrera, S., Tuset, M., Arranz, N., Deckers, C., & Honoré, P. M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2604475 · Cited by 2 · see citing works
Yang, X., Pang, A.-P., Chen, H., Kou, T., Zhang, Y., Huang, L., Liu, Z., & Zheng, Y. (2026) · Biotechnology Journal · doi:10.1002/biot.70217 · Cited by 1 · see citing works
Macrocyclic peptides as protein–protein interaction modulators: a review
Sunny, E. A. S., & Sadanandan, S. (2026) · Organic & Biomolecular Chemistry · doi:10.1039/d6ob00106h · Cited by 2 · see citing works
(2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad138 · Cited by 1 · see citing works
Aspergillus-Human Interactions: From the Environment to Clinical Significance
Thammahong, A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98509
Clinical status of anticandidal therapeutic agents
Kumar, A., & Jha, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18744-5.00004-6
Contemporary Management of Pediatric Invasive Fungal Rhinosinusitis
Zhou, S., Yu, A. J., Frank, E. D., Valencia‐Sanchez, B. A., Chen, S. D., Polster, S. P., & Patel, V. A. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00844-w
Invasive Fungal Disease in Immunocompromised Children: Current and Emerging Therapies
Brophy‐Williams, S., Ewe, K. Y. H., & Yeoh, D. K. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00848-6
Groll, A. H., & Walsh, T. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00256-9
Samajdar, S. S., Chatterjee, R., & Mukherjee, S. (2026) · One Health Bulletin · doi:10.4103/ohbl.ohbl_57_25
Fernández-Fernández, R., García-Martínez, R., Sánchez-Yebra, W., Chueca, N., & Colmenero, M. (2026) · Microorganisms · doi:10.3390/microorganisms14030683
Yin, Y., Zhao, Y., Zhao, M., Zhang, L., Li, R., & Liu, L. (2026) · Journal of Fungi · doi:10.3390/jof12080565
Novel antifungal agents for treating endemic mycoses: hope on the horizon?
Bahr, N. C., Pasqualotto, A. C., & Thompson, G. R. (2026) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001225
Self-citationMartín‐Loeches, I., & Yu, Y. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2726965
Emerging therapies for Candidozyma auris ( Candida auris) : current landscape and future directions
Zhang, L., Felix, L. O., & Mylonakis, E. E. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2740114
Kłos, M., Janeczko, M., Mickiewicz, B., Kozyra, P., & Kubiński, K. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2736311
- Authors
- Ham, Y. Y., Lewis, J. S., & Thompson, G. R.
- Affiliations
- Department of Pharmacy,Oregon Health & Science University, Portland, OR 97239, USA
- Oregon Health & Science University (US)
- Venue
- Future Microbiology
- Publisher
- Informa UK Limited
- Published
- 2021-01
- Volume
- 16
- Issue
- 1
- Pages
- 27-36
- ISSN
- 1746-0913 (ISSN-L)
- 1746-0921
- OpenAlex
- W3120379295
- Cited by
- 66
- References
- 31
- Citations by year
- 2026: 13 · 2025: 9 · 2024: 15 · 2023: 15 · 2022: 10 · 2021: 4
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Future Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- JS Lewis
- Gilead, Merck, Regeneron and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- rezafungin, invasive candidiasis, candidemia, antifungal agents, echinocandins, candidiasis prophylaxis, bone marrow transplant recipients, immunocompromised patients, drug safety, drug efficacy
- MeSH terms
- Antifungal Agents, Candida, Humans, Randomized Controlled Trials as Topic, Immunocompromised Host, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
